- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00177684
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subject's visit for teaching and administration of the first dose of aerosolized liposomal Amphotericin will be performed at the specified intervals before the scheduled bronchoscopy.
Subject will receive first dose of the aerosolized liposomal amphotericin under direct supervision of physician and study coordinator. This visit will last approximately 2 hours.
Subject's spirometry will be performed before (standard of care) and after the administration (research related) of first dose aerosolized liposomal amphotericin. Each spirometry measurement takes approximately 1 hour. Prior to administration, blood pressure and heart rate will be obtained.
In the absence of any significant side effect of the aerosolized liposomal amphotericin (e.g., wheezing, shortness of breath, drop in FEV1 > 15%, the remaining three doses will be dispensed to the patient through pharmacy. The subject will be instructed on how to measure his/her peak flow rate before and after taking the aerosolized liposomal amphotericin. (approximately 1 hour) A 24 hr study pager number will be given to subjects to contact the investigators in case of development of side effects such as shortness of breath, wheezing, heaviness in the chest.
The study coordinator will contact the subject daily to ensure the compliance with the aerosolized liposomal amphotericin administration and monitor any untoward effects. This phone contact will not take longer than 10 minutes of the participant's time.
Drug administration: Subjects will be dispensed vials of ABELCET ® and will be taught by the study coordinator/investigators to draw drug from the vial to nebulizer. Detailed written instructions will also be provided to the subjects. In addition subjects will prove the comprehension of the instructions by demonstrating the procedure, to the study coordinator during initial visit. The description for the patient is as follows "Before administering the drug via nebulization, shake the vial gently until there is no evidence of any yellow sediment at the bottom. Withdraw the appropriate dose of ABELCET ® from the required number of vials into one or more sterile syringes using an 18-gauge needle. Remove the needle from each syringe filled with ABELCET ® and replace with the 5-micron filter needle supplied with each vial. Put no more than 7 ml of ABELCET ® in the nebulizer and inhaled over a period of 15 minutes. Continue the inhalation process until whole the amount is used up. Repeat the procedure with additional drug if your doctor has prescribed more drug for you". Aero Eclipse Nebulizer and Devilbliss 8650D compressor will be used for the study.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female lung transplant recipients at University of Pittsburgh Medical Center ≥ 18yrs of age will be eligible for the study. Subjects HIV status will not determine the exclusion from study.
Exclusion Criteria:
- Pregnant women or women who are currently breast-feeding an infant
- Hypersensitive to amphotericin deoxycholate or lipid complex amphotericin B (Abelcet ®)
- Have a documented fungal infection
- Receipt of inhalational or IV amphotericin B within last 30 days
- Have a Temp ≥ 38ºC
- Hypoxemic (pulse oximeter < 92% at room air.)
- On mechanical ventilator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®).
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and serum with the administration of a four days of lipid complex of amphotericin B (Abelcet ®) (QD) via aerosolized nebulization in lung transplant recipients.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Mark Ludwig, Enzon Pharmaceuticals, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB # 0407015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Transplantation
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Emory UniversityCompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Heart-Lung TransplantationUnited States
-
Astellas Pharma IncCompletedHeart Transplantation | Lung Transplantation | Pancreas (Including SPK) TransplantationFrance, United Kingdom, Taiwan, Belgium, Italy, Austria
-
Hannover Medical SchoolUnknownExercise Training | Lung Transplantation | Psychotherapy | Heart-Lung Transplantation | "Rehabilitation"Germany
-
University of AlbertaNatera, Inc.; One LambdaRecruiting
-
Universidad Complutense de MadridHospital Universitario 12 de OctubreRecruiting
-
KU LeuvenCompleted
-
Hopital FochCompleted
-
Emory UniversityTerminated
-
Hannover Medical SchoolCorscience, Inc.CompletedLung TransplantationGermany
Clinical Trials on Amphotericin B
-
Bharat Serums and Vaccines LimitedMinistry of Science and TechnologyCompletedLeishmaniasis, VisceralIndia
-
Aurobindo Pharma LtdAxis Clinicals LimitedCompletedVisceral LeishmaniasisBangladesh, India
-
Astellas Pharma Global Development, Inc.TerminatedCandidiasisPhilippines, United States, Canada, Israel, Romania, Greece, Turkey, Brazil, Bulgaria, Colombia, Hungary, Ukraine
-
Banaras Hindu UniversityCompletedVisceral LeishmaniasisIndia
-
Southeast University, ChinaCompleted
-
LiposomeCompletedHIV Infections | Meningitis, CryptococcalUnited States
-
Peking Union Medical College HospitalRecruiting
-
Taiwan Liposome CompanyCompleted
-
European Organisation for Research and Treatment...CompletedCancerBelgium, Netherlands, Italy, Hungary, France, Spain, Germany, Israel, Czech Republic, United Arab Emirates, Sweden, Greece, Turkey, Portugal, Slovakia
-
Matinas BioPharma Nanotechnologies, Inc.CompletedCandidiasis, Chronic MucocutaneousUnited States